JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5. Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of
Acid-sensing ion channel 3 mediates pain hypersensitivity associated with high-fat diet consumption in mice
PAIN 2024 Feb 1;165(2):470-486. doi: 10.1097/j.pain.0000000000003030. Ahmed Negm, Katharina Stobbe, Selma Ben Fradj, Clara Sanchez, Arnaud Landra-Willm, Margaux Richter, Lucile Fleuriot, Delphine Debayle, Emmanuel Deval, Eric Lingueglia, Carole Rovere, Jacques Noel Abstract Lipid-rich diet is the major cause of obesity, affecting 13% of the worldwide adult population. Obesity is a